NCT03100591View on ClinicalTrials.gov

A Study to Evaluate ACT-132577 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 28, 2017

Primary Completion Date

April 18, 2017

Study Completion Date

April 18, 2017

Conditions
Healthy Subjects
Interventions
DRUG

14C-radiolabeled ACT-132577

Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie \[μCi\]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg

Trial Locations (1)

Unknown

PRA Health Sciences, Groningen

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT03100591 - A Study to Evaluate ACT-132577 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter